drugset
drugset / Trial / NCT07467993

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT07467993 ↗

Phase 2 Recruiting 142 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

Timeline

Start
2026-03-16
Primary completion
2027-07-29
Completion
2027-07-29

Drugs

EvaluationDrugModalityDoseRoute
Subject GXV813 Unknown — Oral

Indications

schizophrenia